Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
Sujit V Janardhan, Nancy S Reau Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA Abstract: Chronic hepatitis C virus (HCV) infection represents a global health problem that affects up to 130–...
Saved in:
Main Authors: | Janardhan SV, Reau NS |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/b87ffaa4cb8b4d57b149574f3fe3c7a4 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
by: Atsushi Hosui, et al.
Published: (2021) -
Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated
by: JIANG Yingying
Published: (2021) -
In Vivo Studies Should Take Priority When Defining Mechanisms of Intestinal Crypt Morphogenesis
by: Jordi Guiu, PhD, et al.
Published: (2022) -
Rebuttal to: In Vivo Studies Should Take Priority When Defining Mechanisms of Intestinal Crypt Morphogenesis
by: Shinya Sugimoto, MD, PhD, et al.
Published: (2022) -
Patients in the indeterminate phase of chronic hepatitis B virus infection should receive active antiviral therapy
by: WANG Jingyue
Published: (2021)